Human Growth Hormone Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook
Date : November 2024
Human Growth Hormone Market Size Analysis and Top Companies
The global human growth hormone market size is estimated at to hit around USD 20.78 billion by 2033 from USD 7.20 billion in 2024 with a CAGR of 12.5% from 2024 to 2033. The top companies operating in the human growth hormone market are Novo Nordisk, Merck & Co., Eli Lilly & Company, Pfizer Inc., Teva Pharmaceutical Industries, Novartis AG, Anhui Anke Biotechnology (Group) Co., Ltd, Roche, Ipsen, Ferring BV, and others.
Market Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 7.20 Billion |
| Market Size by 2034 | USD 23.38 Billion |
| Growth Rate from 2024 to 2034 | CAGR of 12.5% |
| Fastest Growing Region | Asia-Pacific |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2034 |
| Segments Covered | By Application, By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Human Growth Hormone Market Companies
- Novo Nordisk
- Merck & Co.
- Eli Lilly & Company
- Pfizer Inc.
- Teva Pharmaceutical Industries
- Novartis AG
- Anhui Anke Biotechnology (Group) Co., Ltd
- Roche
- Ipsen
Recent Developments
- February 2021: The Pfizer and OPKO Health Inc. announced that the European Medicines Agency has authorised Somatrogon for the treatment of individuals lacking in juvenile growth hormone. Pfizer and OPKO have been working together to develop and market Somatrogon for GHD therapy since 2014.
We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344
Keypoints
- Company Overview
- Locations & Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Corporate Strategy
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking